Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia LoRusso(Yale Cancer Center), Alejandro D. Ricart(Pfizer (United States)), Lisle M. Nabell(Memorial Sloan Kettering Cancer Center), Samuel E. DePrimo(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), Smitha Krishnamurthi(Cleveland Clinic), Steven Bentivegna(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Lisa Malburg(Memorial Sloan Kettering Cancer Center), John J. Rinehart(Memorial Sloan Kettering Cancer Center), Weiwei Tan(Memorial Sloan Kettering Cancer Center)
Cited by 250
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k